|Day Low/High||62.42 / 63.12|
|52 Wk Low/High||47.97 / 64.00|
Each of these companies pays extremely safe dividends, yields over 2%, and doesn't appear to be extremely overvalued like many other dividend-paying stocks in the market today.
The tactic is a slightly out-of-the-money, bearishly biased vertical put spread expiring in November.
The market continues to defy those players who believe we are seeing the calm before the storm.
The FDA approved Merck's Keytruda, a drug to treat metastatic and recurrent cancer.
Shareholders of the oncology drug maker ought to be satisfied with the auction's conclusion.
Pfizer confirmed its $14 billion acquisition of cancer drugmaker Medivation on Monday.
Don't be surprised; we view Bristol-Myers as "down, not out."
Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.
Merck (MRK), along with at least four other pharmaceuticals companies, has reportedly shown interest in acquiring Medivation (MDVN).
Besides Tesla, Twitter and Biogen make good candidates.
BMY is unlikely to stay in the low $60s for long.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the publication of results from C-EDGE CO-STAR.
Stocks retreat from record highs on Monday as a selloff in health care overshadows a rally in energy.
The failed trial is among the biggest single blows by a major pharma player.
Stocks pull slightly lower on Monday as a selloff in health care squares off against a rally in energy.
Credit Suisse downgraded Bristol-Myers Squibb to NEUTRAL from OUTPERFORM and lowered its price target to $63 from $86 following the latest announcement on Opdivo.
Stocks pull lower on Monday morning as a selloff in health care sours the jobs-inspired rally that pushed benchmark indices to record highs last week.
One day does not make a trend, but one day can certainly reinforce an existing trend.
Merck (MRK) stock was upgraded to 'outperform' at Credit Suisse after Bristol-Myers's (BMY) non-small cell lung cancer treatment missed its primary endpoint.
Here's a technical look at how to trade some of the most active stocks on the market right now.
Mattress Firm soars on takeover bid, while Delta's worldwide computer issues are causing the stock to drop.
Here are Monday's top research calls, including downgrades for Bristol-Myers Squibb, JPMorgan and Weyerhaeuser, and an upgrade for Merck.
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.
In highlights from this week's trading diary and posts, Kass tells us why self-confident, glib and dogmatic is no way to go through life, son.